Nutriband Inc is a biotechnology company focused on the development and commercialization of innovative transdermal drug delivery systems and other advanced technologies for the pharmaceutical and healthcare industries
By leveraging cutting-edge research and proprietary platforms, the company aims to enhance the efficacy and safety of medications, providing solutions that improve patient compliance and therapeutic outcomes. Their product pipeline includes a range of applications, from pain management to the treatment of various medical conditions, reflecting their commitment to advancing healthcare through technology.
In this video, I review the market warnings I've shared over the past three weeks and how Friday's session confirmed negative divergences across key metrics signaling weakness.
Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments
The AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4th to primarily discuss the company’s AVERSA technology.
Nutriband (NASDAQNTRB), a pharmaceutical company with a special focus on transdermal technologies, will be part of an upcoming live webinar hosted by RedChip Companies. Scheduled for October 17, 2024, at 4:15 p.m. ET, the exclusive event will feature Gareth Sheridan, Founder and CEO, and Serguei Melnik, Founder and President. Sheridan and Melnik will share insight into Nutriband’s current operations and upcoming milestones as well as field questions from listeners and investors.
Nutriband (NASDAQNTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more.
PALM BEACH, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as fentanyl, by incorporating aversive agents into transdermal patches. Abuse-deterrent opioid formulations (ADFs) are designed to make it more difficult to abuse opioids by making them less attractive or rewarding, or by increasing the difficulty of manipulating them. ADFs can help reduce the risk of adverse effects associated with snorting or injecting opioids, and may also help prevent medication errors. Active companies in the industry include: Nutriband Inc. (NASDAQNTRB), Teva Pharmaceutical Industries Ltd. NYSE: TEVANYSETEVA)(NYSE: LLYNYSELLY, Novartis AG (NYSE: NVSNYSE), Amneal Pharmaceuticals, Inc. (NASDAQ: AMRXAMRX).
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products […]
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology
Nutriband (NASDAQNTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According to the company, AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch.
